One company cited by the Federal Trade Commission claimed its products “work like magic”
The Federal Trade Commission (FTC) in the U.S. has issued a stern message to CBD companies: Cite your work.
The popularity of the drug has exploded in the U.S. since Congress legalized hemp late last year, and as companies battle for a share of the market for their gummies and capsules, the truth has often become the first casualty.
One company cited by the FTC claimed its products “work like magic,” treating even the most intense pain more effectively than opioids. It also stated that CBD has been proven to be an effective treatment for everything from Alzheimer’s disease and multiple sclerosis to fibromyalgia and nicotine addiction.
A second company listed autism, anorexia, bipolar disorder, PTSD, Lou Gehrig’s disease and AIDS as treatable by their CBD products.
The letters from the FTC urge companies to review all advertising, including customer testimonials, to guarantee that any claims are backed by reliable scientific evidence. Failure to do so could result in injunctions and an order to refund deceived consumers. Companies must respond to the FTC within 15 days explaining how they are addressing concerns.
The FTC has struggled recently with how to best regulate CBD and is currently considering a model that will treat it as a dietary supplement.
Want to keep up to date on what’s happening in the world of cannabis? Subscribe to the Cannabis Post newsletter for weekly insights into the industry, what insiders will be talking about and content from across the Postmedia Network.
Written by David Yasvinski